Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 12/20 | 0.45 |
| ▸ | GIPR | P48546 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PHGDH | O43175 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3402318 | 0.85 | GCGR (0.49) | GCGRGIPRKCNH2 | |
| SCHEMBL718652 | 0.75 | OXER1 (0.48) | PHGDH | |
| SCHEMBL721063 | 0.73 | MAPT (0.40) | PHGDH | |
| SCHEMBL717614 | 0.69 | CCKBR (0.38) | GCGRGIPRKCNH2PHGDH | |
| SCHEMBL2669829 | 0.68 | GCGR (0.49) | GCGRGIPRKCNH2HDAC3HDAC1 | |
| SCHEMBL926750 | 0.67 | GCGR (0.57) | GCGRGIPRKCNH2 | |
| SCHEMBL926749 | 0.67 | GCGR (0.57) | GCGRGIPRKCNH2 | |
| SCHEMBL2662316 | 0.67 | GCGR (0.57) | GCGRGIPRKCNH2 | |
| SCHEMBL3397752 | 0.67 | CCKBR (0.39) | GCGRGIPRKCNH2PHGDH | |
| SCHEMBL718772 | 0.66 | GCG (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | GCGR 90/4885GIPR 41/4885KCNH2 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.